Research programme: therapeutic cancer vaccines - IRX Therapeutics

Drug Profile

Research programme: therapeutic cancer vaccines - IRX Therapeutics

Alternative Names: IRX 4; IRX 5; IRX 6

Latest Information Update: 17 Jun 2010

Price : $50

At a glance

  • Originator IRX Therapeutics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Jun 2010 IRX Therapeutics raises $US8 million in funds through a note offering to existing shareholders; funds will be used to further develop the company's cancer vaccine programmes
  • 28 May 2007 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top